

Q1 Trends in Trading Activity

FIA's Quarterly Webinar on Trends in Global Futures and Options Volume and Open Interest

Presenters



Will Acworth MODERATOR Senior Vice President, Publications, Data, and Research, FIA



Alex Kramm Managing Director and Senior Equity Research Analyst, UBS




Keith ParkerManaging Director and Head
of US and Global Equity
Strategy, UBS



First Quarter of 2021 Sets Another Record for Trading Volume

Global Futures and Options Volume By Quarter





Global Futures and Options: Volume and Open Interest by Region and Category

Global Futures and Options Volume by Region

Region	Jan-Mar 2021 Vol	YoY Change	% Change	2021 Mar OI	YoY Change	% Change
Asia-Pacific	6,533,546,013	2,128,810,055	48.3%	94,873,066	9,499,437	11.1%
North America	4,037,301,168	449,886,903	12.5%	534,164,893	68,373,496	14.7%
Latin America	2,195,058,851	835,512,089	61.5%	174,524,202	-21,051,526	-10.8%
Europe	1,460,547,532	-311,834,849	-17.6%	251,382,642	-4,314,231	-1.7%
Other	601,889,814	319,064,559	112.8%	28,215,145	12,443,909	78.9%
Total	14,828,343,378	3,421,438,757	30.0%	1,083,159,948	64,951,085	6.4%

Global Futures and Options Volume by Category

Category	Jan-Mar 2021 Vol	YoY Change	% Change	2021 Mar Ol	YoY Change	% Change
Equity Index	5,906,393,062	1,336,943,172	29.3%	279,718,478	-75,144,520	-21.2%
Individual Equity	3,697,810,356	1,661,773,131	81.6%	479,445,095	139,628,848	41.1%
Currency	1,307,490,590	209,516,004	19.1%	33,910,601	5,056,713	17.5%
Interest Rates	1,260,497,529	-280,683,887	-18.2%	177,381,317	-6,696,845	-3.6%
Agriculture	728,972,541	166,463,801	29.6%	25,773,229	3,493,221	15.7%
Energy	722,749,973	-171,945,479	-19.2%	63,230,544	-4,066,387	-6.0%
Other	525,121,108	334,811,814	175.9%	8,761,980	2,760,108	46.0%
Non-Precious Metals	442,883,248	122,887,152	38.4%	9,785,820	-174,103	-1.7%
Precious Metals	236,424,971	41,673,049	21.4%	5,152,884	94,050	1.9%
Total	14,828,343,378	3,421,438,757	30.0%	1,083,159,948	64,951,085	6.4%



Top Five Exchanges by Volume

Rank	Exchange	Jan-Mar 2021 Volume	YoY% Change	End Mar 2021 OI	YoY% Change
1	National Stock Exchange of India	3,130,045,825	69.7%	14,101,263	40.3%
2	B3	2,163,713,963	61.6%	171,298,349	-11.3%
3	CME Group	1,331,452,406	-20.5%	100,748,937	-18.2%
	Chicago Mercantile Exchange	651,929,218	-21.4%	56,297,482	-24.9%
	Chicago Board of Trade	494,198,839	-16.3%	28,391,682	-3.0%
	New York Mercantile Exchange	145,457,427	-28.1%	13,998,931	-13.4%
	Commodity Exchange (COMEX)	39,866,922	-24.9%	2,060,842	-25.5%
4	Nasdaq	911,190,559	53.0%	6,593,865	13.3%
	Nasdaq PHLX ¹	316,221,067	56.6%	n/a	n/a
	Nasdaq Options Market ¹	193,390,508	16.7%	n/a	n/a
	Nasdaq ISE ¹	189,456,040	42.5%	n/a	n/a
	Nasdaq GEMX ¹	143,451,952	142.9%	n/a	n/a
	Nasdaq MRX ¹	33,135,929	518.3%	n/a	n/a
	Nasdaq Exchanges Nordic Markets	18,055,967	-32.7%	6,414,498	13.7%
	Nasdaq BX Options ¹	17,323,435	390.8%	n/a	n/a
	Nasdaq Commodities	155,661	-21.7%	179,367	-1.1%
5	Intercontinental Exchange	885,824,059	10.6%	81,751,695	3.9%
	ICE Futures Europe	327,640,618	-17.7%	50,950,657	7.2%
	NYSE Arca ¹	257,474,396	58.2%	n/a	n/a
	NYSE Amex ¹	214,182,223	68.0%	n/a	n/a
	ICE Futures U.S.	86,026,128	-23.2%	30,789,727	-1.2%
	ICE Futures Singapore	484,610	-6.5%	352	8.0%
	ICE Futures Abu Dhabi ²	16,084	n/a	10,959	n/a



¹ Open Interest for these exchanges attributed to OCC 2 ICE Futures Abu Dhabi began trading in March 2021


Next 10 Top Exchanges by Trading Volume

Rank	Exchange	Jan-Mar 2021 Vol	YoY Change	% Change	2021 Mar Ol	YoY Change	% Change
6	CBOE Holdings	789,135,382	103,278,116	15.1%	368,798	133,525	56.8%
	Cboe Options Exchange ¹	387,541,450	5,314,166	1.4%	n/a	n/a	n/a
	Cboe BZX Options Exchange ¹	214,966,429	44,846,517	26.4%	n/a	n/a	n/a
	Cboe EDGX Options Exchange ¹	90,237,214	31,607,095	53.9%	n/a	n/a	n/a
	Cboe C2 Options Exchange ¹	80,777,957	26,412,193	48.6%	n/a	n/a	n/a
	Cboe Futures Exchange	15,612,332	-4,901,855	-23.9%	368,798	133,525	56.8%
7	Korea Exchange	673,982,169	65,998,971	10.9%	12,093,328	2,534,745	26.5%
8	Zhengzhou Commodity Exchange	634,056,462	388,713,773	158.4%	10,281,630	4,027,332	64.4%
9	Shanghai Futures Exchange	631,383,504	241,127,602	61.8%	7,000,182	-393,267	-5.3%
	Shanghai Futures Exchange	612,174,047	227,805,597	59.3%	6,770,943	-472,289	-6.5%
	Shanghai International Energy Exchange	19,209,457	13,322,005	226.3%	229,239	79,022	52.6%
10	Dalian Commodity Exchange	552,423,337	125,195,874	29.3%	9,888,628	435,400	4.6%
11	Moscow Exchange	542,909,004	-40,849,810	-7.0%	10,133,492	4,052,344	66.6%
12	Borsa Istanbul	540,750,400	315,803,439	140.4%	12,044,431	7,059,633	141.6%
13	Eurex	466,508,380	-164,672,340	-26.1%	143,907,883	-11,410,200	-7.3%
14	BSE	371,807,628	162,061,926	77.3%	2,926,670	605,535	26.1%
	BSE	308,702,493	111,895,928	56.9%	2,925,417	604,292	26.0%
	India International Exchange	63,105,135	50,165,998	387.7%	1,253	1,243	12430.0%
15	Miami International Holdings ¹	323,273,983	150,791,182	87.4%	n/a	n/a	n/a
	MIAX Pearl ¹	121,671,476	44,516,500	57.7%	n/a	n/a	n/a
	MIAX Options ¹	105,643,867	39,063,373	58.7%	n/a	n/a	n/a
	MIAX Emerald ¹	95,958,640	67,211,309	233.8%	n/a	n/a	n/a



Equity Trading: Main Driver for Higher Volume

Quarterly Volume in Equity Futures and Options






Top 20 Equity Index Futures and Options

Rank	Contract	Jan-Mar 2021 Volume	YoY% Change	End Mar 2021 OI	YoY% Change
1	Bank Nifty Index Options, National Stock Exchange of India	1,565,572,442	77.0%	1,084,619	207.6%
2	Mini Ibovespa Index (WIN) Futures, B3	1,080,259,315	79.3%	1,035,155	-13.7%
3	CNX Nifty Index Options, National Stock Exchange of India	893,860,424	110.9%	2,040,265	101.0%
4	SPDR S&P 500 ETF Options *	271,684,968	-8.6%	18,719,106	-31.6%
5	Kospi 200 Options, Korea Exchange	157,353,092	-24.5%	1,965,576	-11.1%
6	E-mini S&P 500 Futures, Chicago Mercantile Exchange	111,099,369	-31.4%	2,585,446	-24.8%
7	Powershares QQQ ETF Options *	77,457,015	34.7%	9,253,548	44.5%
8	S&P 500 Index (SPX) Options, Cboe Options Exchange	74,349,332	-30.1%	12,918,784	-31.1%
9	Micro E-mini Nasdaq 100 Index Futures, Chicago Mercantile Exchange	66,625,840	96.6%	69,120	31.9%
10	Micro E-mini S&P 500 Index Futures, Chicago Mercantile Exchange	64,286,399	50.9%	90,455	11.2%
11	Euro Stoxx 50 Index Futures, Eurex	63,229,548	-52.7%	2,999,856	-35.0%
12	Euro Stoxx 50 Index Options, Eurex	62,282,783	-42.1%	33,293,602	-19.7%
13	India 50 Index Options, India International Exchange	61,215,820	412.3%	371	7320.0%
14	Nikkei 225 Mini Futures, Osaka Exchange	60,837,567	-48.8%	372,060	-44.1%
15	Taiex (TXO) Options, Taiwan Futures Exchange	53,663,421	-6.9%	307,610	-59.8%
16	iShares Russell 2000 ETF Options *	44,655,700	45.3%	6,823,328	12.6%
17	Kospi 200 Weekly Options, Korea Exchange	41,019,366	57.8%	118,324	549.5%
18	RTS Index Futures, Moscow Exchange	40,510,842	-4.0%	373,240	-27.5%
19	CBOE Volatility Index (VIX) Options, Cboe Options Exchange	37,023,785	-24.7%	7,797,124	-25.9%
20	E-mini Nasdaq 100 Futures, Chicago Mercantile Exchange	36,965,964	-17.9%	222,778	19.4%



Rates Trading: Strong Recovery in Q1


Quarterly Volume in Interest Rate Futures and Options






Rates Trading: CME Volume Returns to Pre-Covid Levels But Open Interest Lags

Trading Volume by Month




Open Interest by Month






Rates Trading: Eurex Volume Reaches 66 Million Contracts in March, Almost Matching Pandemic Peak

Trading Volume by Month




Open Interest by Month






Rates Trading: SONIA and SOFR Futures Trading Accelerates in Q1, OI Surpasses 1 Mn in Feb

Trading Volume by Month



Open Interest by Month






Top 20 Interest Rates Futures and Options

Rank	Contract	Jan-Mar 2021 Vol	% Change	2021 Mar OI	% Change
1	One-Day Interbank Deposit (DI1) Futures, B3	169,402,741	7.8%	27,802,730	26.7%
2	Eurodollar Futures, Chicago Mercantile Exchange	165,631,715	-25.9%	11,407,230	5.8%
3	10 Year Treasury Note Futures, Chicago Board of Trade	134,477,195	-11.7%	3,892,960	19.5%
4	5 Year Treasury Note Futures, Chicago Board of Trade	79,549,075	-12.6%	3,585,357	-6.8%
5	Average One-Day Interbank Deposit Rate Index (IDI) Options, B3	60,045,105	-25.4%	35,677,925	-7.1%
6	Euro-Bund Futures, Eurex	56,306,346	1.3%	1,221,214	16.9%
7	Eurodollar Mid-Curve Options, Chicago Mercantile Exchange	52,674,984	75.2%	16,790,379	77.1%
8	3 Month Euribor Futures, ICE Futures Europe	48,151,286	-20.9%	3,523,175	9.9%
9	3 Month Sterling Futures, ICE Futures Europe	45,181,627	-27.6%	4,533,472	34.4%
10	10 Year Treasury Note Options, Chicago Board of Trade	44,921,629	-17.5%	3,255,387	-10.8%
11	30 Year Treasury Bond Futures, Chicago Board of Trade	32,518,111	7.1%	1,185,169	18.4%
12	Euro-Bobl Futures, Eurex	32,324,842	1.1%	1,064,991	18.5%
13	2 Year Treasury Note Futures, Chicago Board of Trade	30,597,806	-46.7%	2,352,959	-17.6%
14	Ultra 10 Year Treasury Note Futures, Chicago Board of Trade	25,121,552	24.0%	1,394,104	84.5%
15	Euro-Schatz Futures, Eurex	23,645,058	-9.5%	1,436,492	51.9%
16	Long Gilt Futures, ICE Futures Europe	19,372,682	10.1%	649,471	58.0%
17	Iboxx High Yield Corporate Bond ETF Options *	19,002,475	-21.6%	5,246,134	-2.4%
18	10 Year Treasury Bond Futures, ASX 24	17,709,158	10.9%	1,295,646	9.6%
19	Ultra Treasury Bond Futures, Chicago Board of Trade	15,684,539	-3.6%	1,135,760	8.0%
20	Eurodollar Options, Chicago Mercantile Exchange	14,763,762	-87.5%	17,029,786	-58.3%



Commodities: Chemicals and Plastics in 'Other' Category Driving Recent Volume Increases


Quarterly Volume in Commodity Futures and Options





China: Rapid Growth in Trading of Futures in Agriculture and 'Other' Categories


Quarterly Volume by Category





China: Aggregate Open Interest Has Doubled Over Last Five Years

End of Quarter Open Interest by Category



Based on data from five exchanges in mainland China: CFFEX, DCE, INE, SHFE and ZCE



Top 20 Energy Futures and Options

		Jan-Mar 2021			%
Rank	Contract	Vol	% Change	2021 Mar OI	Change
1	Brent Oil Futures, Moscow Exchange	137,602,880	-42.9%	1,698,242	76.5%
2	Fuel Oil Futures, Shanghai Futures Exchange	81,246,101	-22.9%	317,959	-66.8%
3	Brent Crude Oil Futures, ICE Futures Europe	67,348,820	-14.2%	2,543,697	-2.8%
	WTI Light Sweet Crude Oil (CL) Futures, New York Mercantile				
4	Exchange	67,067,189	-29.5%	2,347,818	0.3%
5	Thermal Coal (ZC) Futures, Zhengzhou Commodity Exchange	39,497,129	666.4%	380,853	16.3%
6	Bitumen Futures, Shanghai Futures Exchange	34,353,155	-6.5%	492,147	-37.6%
7	North American Natural Gas Futures, ICE Futures U.S.	32,542,764	-21.6%	15,485,087	-1.0%
8	Henry Hub Natural Gas (NG) Futures, New York Mercantile Exchange	25,582,922	-28.0%	1,203,608	-1.7%
9	Gas Oil Futures, ICE Futures Europe	22,161,266	-21.2%	967,416	9.7%
10	Coke Futures, Dalian Commodity Exchange	16,922,152	133.0%	198,765	30.8%
11	WTI Light Sweet Crude Oil Futures, ICE Futures Europe	15,061,161	-11.6%	542,000	-21.9%
12	Hard Coking Coal Futures, Dalian Commodity Exchange	13,056,928	261.7%	182,535	70.5%
13	Global Oil Products Futures, ICE Futures Europe	12,968,910	-10.0%	4,140,029	-1.1%
14	Natural Gas Futures, Multi Commodity Exchange of India	12,733,341	33.4%	14,347	48.1%
15	RBOB Gasoline Physical (RB) Futures, New York Mercantile Exchange	12,455,147	-17.2%	373,548	2.9%
	Medium Sour Crude Oil Futures, Shanghai International Energy				
16	Exchange	11,444,683	124.8%	76,656	-39.6%
17	Heating Oil Futures, ICE Futures Europe	10,490,526	-8.0%	34,738	32.4%
18	North American Natural Gas and Power Options, ICE Futures U.S.	10,384,896	-8.0%	5,494,189	7.8%
19	NY Harbor ULSD (HO) Futures, New York Mercantile Exchange	10,347,907	-30.8%	409,965	16.0%
20	Dutch TTF Gas Futures, ICE Futures Europe	8,974,481	11.6%	1,688,251	11.0%




Crude Oil Futures: Battle of the Benchmarks






Copper Futures: Tri-Polar Market





Explosive Growth in the Trading of Single Stock Options on US Exchanges

US Single Stock Option Volume






Explosive Growth in the Trading of Single Stock Options on US Exchanges

	2021 Jan-Mar	2020 Jan-Mar		
Exchange Name	Volume	Volume	YoY Change	% Change
Nasdaq PHLX	225,622,004	119,490,231	106,131,773	88.8%
NYSE Arca	191,375,695	93,998,598	97,377,097	103.6%
Cboe Options Exchange	181,897,806	129,757,694	52,140,112	40.2%
Nasdaq Options Market	146,819,570	102,753,867	44,065,703	42.9%
NYSE Amex	142,970,048	53,863,226	89,106,822	165.4%
Cboe BZX Options	140,593,750	97,049,936	43,543,814	44.9%
Nasdaq GEMX	123,575,936	37,349,338	86,226,598	230.9%
Nasdaq ISE	121,883,698	58,976,481	62,907,217	106.7%
MIAX Pearl	87,708,041	40,449,447	47,258,594	116.8%
Boston Options Exchange	79,785,187	28,895,755	50,889,432	176.1%
MIAX Emerald	78,419,501	18,706,713	59,712,788	319.2%
MIAX Options	76,934,960	37,418,491	39,516,469	105.6%
Cboe EDGX Options Exchange	64,443,912	35,486,093	28,957,819	81.6%
Cboe C2 Options Exchange	42,524,380	19,082,077	23,442,303	122.8%
Nasdaq MRX	25,231,735	3,977,122	21,254,613	534.4%
Nasdaq BX Options	13,910,467	2,525,849	11,384,618	450.7%



Rise of Retail: Micros vs Cryptos

Monthly Futures Volume on CME





Rise of Retail: Crypto Futures at CME






Rise of Retail: New Accounts in US Futures Markets

- CFTC Staff Presentation at Global Markets Advisory Committee March 11
- Large spike in new accounts in Q1 2020
- Analysis shows most retail traders seek shorter-term trends
- "High correlation" between social media attention and increased participation

New Accounts Opened

All U.S. Designated Contract Markets








US Equity Strategy Presentation

Rise of retail: will it last, what are the impacts?

Keith Parker

Head of US and Global Equity Strategy Tel: +1-212-713 3296 keith-j.parker@ubs.com




Retail volume has surged

Retail volumes as a % of total (rolling monthly, normalized to 2018)

2.2 Retail volumes as % total, normlalized relative to 2018 2.0 1.8 1.6 1.0 1.0 Retail share of total volumes rose rapidly 0.6 Jan-17 Jul-17 Jan-18 Jul-18 Jan-19 Jul-19 Jan-20 Jul-20 Jan-21

Daily average revenue trades at retail brokerages



Source: Factset, UBS Data Solutions, UBS Source: Company reports, UBS




Retail ownership and returns in perspective

S&P 500 performance vs. ownership changes

Correlation since 95 = 0.31 Equities rallied when HH+foreign ownership rose 30% 0% 0% -30% -6% -5% -4% Change in US HH + foreign ownership as % of US equities (yoy)

Retail ownership of S&P 500 based on 13F filings




Source: Haver Analytics, UBS Source: Factset, UBS




Demographics point to growing retail influence

Population growth by cohort



Population growth differences and S&P 500 earnings yield minus Baa corp yield




Source: Census Bureau, Haver, FactSet, UBS

Source: Census Bureau, Haver, FactSet, UBS




Age and equity ownership: 35-55yr olds key

Percentage of individuals holding stocks by age cohort



Marginal change in preference for stocks holding by age cohort (pp)




Source: Federal Reserve, UBS Source: Federal Reserve, UBS




UBS retail flows show a jump in net buying

Retail net buying of US stocks as a share of market cap (21d, z-score)

Retail net flows by industry group (as % of market cap, z-score)






Source: Factset, UBS Data Solutions, UBS Source: Factset, UBS Data Solutions, UBS




Retail option activity increased as well, particularly call buying

Retail share of option trading rising (option trades <10 contracts)

Call-Put imbalance as % market cap






Source: OCC, UBS Source: Bloomberg, UBS




Retail Sentiment Indicator - a proprietary signal

Twitter sentiment strength – Sentiment times #Tweets

Retail Sentiment Indicator





Source: Twitter, Bloomberg, UBS

Source: Factset, Bloomberg, UBS Data Solutions, UBS



Retail biases: concentrated buying and selling

Retail purchases and sales have been highly concentrated

Share of absolute flows over the last 12m given ranking of notional flow 30% 31% 37% 25% 20% 15% 10% 5% 0% - 2% 2% - 5% 5% - 10% 30% - 40% 20% - 60% 70% - 80% %06 - %08 10% - 20% 90% - 95% 20% - 30% 40% - 50% %02 - %09 95% - 98% 98%-100%

Performance of retail investors top stocks relative to S&P 500



Source: UBS, Data Solutions, UBS

Source: UBS, Data Solutions, UBS




Retail biases: styles and factors

Beta of retail investors top stocks

2.6 Rolling 3m beta of top retail purcashes to S&P 1500 2.4 2.2 2.0 1.8 1.6 1.4 1.2 1.0 0.8 0.6 15 16 17 18 19 20 14 21

Characteristic of retail investors top stocks bought and sold



Source: Factset, Data Solutions, UBS


Source: Factset, Bloomberg, UBS Data Solutions, UBS. Note: Twitter = total number of financially relevant tweets




Retail matters for stock returns

1m coincident stock return based on retail sentiment strength (higher = more positive)

Forward return in S&P 500 given change in retail sentiment





Source: Factset, Bloomberg, UBS Data Solutions, UBS


Source: Factset, Bloomberg, UBS Data Solutions, UBS




Stock signal? Retail interest and forward returns

3m forward stock return based on retail sentiment strength

12m forward stock return based on retail sentiment strength





Source: Factset, Bloomberg, UBS Data Solutions, UBS

Source: Factset, Bloomberg, UBS Data Solutions, UBS





Rise of Retail

The Impact on Exchanges and Market Structure

Alex Kramm, CFA

Senior Research Analyst Exchanges & Business Services Tel: +1-212-713 4060 alex.kramm@ubs.com

This report has been prepared by UBS Securities LLC.




US cash equities: retail has driven industry volumes higher



16,000 12,000 10,000 8,000 4,000 2,000 0 66,000 10,000

Source: Cboe Note: in millions of shares per day

US cash equity volume by exchange group



Source: Cboe


Note: in millions of shares per day




US equity options: retail participation has increased significantly

Total industry volume

US equity option volume by exchange group





Source: OCC

Note: in thousands of contracts per day

Source: OCC

Note: in thousands of contracts per day




CME Group: new product launches support retail growth

Total micro equity volumes

Source: CME Group

Note: in thousands of contracts per day

Retail as a % of total volume increased from 3.7% to 5.1% from 3Q19 to 1Q21




Source: CME Group

Note: in thousands of contracts per day




CBOE: increased focus on retail and tailored products

VIX and mini VIX futures combined ADV



Source: Cboe Note: Mini VIX futures launched 8/10/2020; in contracts per day

XSP as a % of SPX



Source: Cboe

Note: in contracts per day



Valuation Method and Risk Statement

Equity market returns are influenced by corporate earnings, interest rates, risk premia, as well as other variables influenced by the business cycle. The outlook for any and all of these variables is subject to change.

Risk Statement

Risks of multi-asset investing include but are not limited to market risk, credit risk, interest rate risk, and foreign exchange risk. Correlations of returns among different asset classes may deviate from historical patterns. Geopolitical events and policy shocks pose risks that can reduce asset returns. Valuations may be adversely affected during times of high market volatility, thin liquidity, and economic dislocation.



Required Disclosures

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; certain additional disclosures concerning UBS research recommendations; and terms and conditions for certain third party data used in research report, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 4 May 2021 5:30PM GMT. UBS has designated certain Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations. Quantitative Research Review: UBS publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of an occurrence of a number of short term factors in a product known as the 'Quantitative Research Review'. Views contained in this assessment on a particular stock reflect only the views on those short term factors which are a different timeframe to the 12-month timeframe reflected in any equity rating set out in this note. For the latest responses, please click https://neo.ubs.com/quantitative, or speak to your UBS

Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.



Required Disclosures (continued)

UBS Investment Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage ¹	IB Services ²
Buy	FSR is > 6% above the MRA.	52%	31%
Neutral	FSR is between -6% and 6% of the MRA.	36%	28%
Sell	FSR is > 6% below the MRA.	12%	22%
Short-Term Rating	Definition	Coverage ³	IB Services ⁴
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%

Source: UBS. Rating allocations are as of 31 March 2021.

- 1:Percentage of companies under coverage globally within the 12-month rating category.
- 2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.
- 3:Percentage of companies under coverage globally within the Short-Term rating category.
- 4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS:Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. In some cases, this yield may be based on accrued dividends. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES:UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Sell: Negative on factors such as structure, management, performance record, discount. Core Banding Exceptions (CBE): Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Securities LLC: Keith Parker, Alex Kramm

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.



Global Disclaimer

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG, UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

This Document is provided solely to recipients who are expressly authorized by UBS to receive it. If you are not so authorized you must immediately destroy the Document.

Global Research is provided to our clients through UBS Neo, and in certain instances, UBS com and any other system or distribution method specifically identified in one or more communications distributed through UBS Neo or UBS com (each a system) as an approved means for distributing Global Research. It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.

When you receive Global Research through a system, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the UBS Neo Flatform Use Agreement (the "Neo Terms") together with any other relevant terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, you agree that use shall be subject to this Global Research Disclaimer, the Neo Terms and where applicable the UBS Investment Bank terms of business (http://www.ubs.com/global/en/investment-bank/regulatory.html) and to UBSs Terms of UsBs Terms of UsBs Terms of UsBs Investment (http://www.ubs.com/global/en/investment-bank/regulatory.html) and to UBSs Terms of UsBs Terms of UsBs Terms of UsBs processing your personal data and using cookies in accordance with our Pivacy Statement (http://www.ubs.com/global/en/investment-bank/regulatory.html) and cookies not accordance with our Pivacy Statement (http://www.ubs.com/global/en/investment-bank/regulatory.html) and cookies not accordance with our Pivacy Statement (http://www.ubs.com/global/en/investment-bank/regulatory.html) and cookies not accordance with our Pivacy Statement (http://www.ubs.com/global/en/investment-bank/regulatory.html) and cookies not accordance with our Pivacy Statement (http://www.ubs.com/global/en/investment-bank/regulatory.html) and cookies not accordance with our Pivacy Statement (http://www.ubs.com/global/en/investment-bank/regulatory.html) and cookies not accordance with our Pivacy Statement (http://www.ubs.com/global/en/investment-bank/regulatory.html) and cookies not accordance with the p

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

In certain circumstances (including for example, if you are an academic or a member of the media) you may receive Global Research otherwise than in the capacity of a client of UBS and you understand and agree that (i) the Global Research is provided to you for information purposes only; (ii) for the purposes of receiving it you are not intended to be and will not be treated as a "client" of UBS for any legal or regulatory purpose; (iii) the Global Research must not be relied on or acted upon for any purpose; and (iv) such content is subject to the relevant disclaimers that follow.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature, it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fliduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "In the characteristics and Risks of Sandardized Options". You may read the document at http://www.theos.com/publications/risks/riskchap1.jsp or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, comparisons, ecom/publications/risks/riskchap1.jsp or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, comparisons, ecom/publications/risks/riskchap1.jsp or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, ecom/publications/risks/riskchap1.jsp or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because of the importance of tax considerations to make a comparison of the risks associated with these instruments have a second purchased options. The production of the risks associated with the support of the risks associated risks and the production of the risks associated with the support

Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBSs internal books and records or theoretical model-based valuations and may be based on certain assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or other representative of UBS. Any statements contained in this report attributed to a third party represent UBSs interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any of the Information (including any forecast, value damount ("Values") be used for any of the following purposes:

(i) valuation or accounting purposes;

(ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or

(iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit <a href="https://pressures.org/limiting/limi

Research will initiate, update and cease coverage solely at the discretion of UBS Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms under English law or, if not carried out by UBS in the UK the law of the relevant jurisdiction in which UBS determines it carries out the activity) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Within the past 12 months UBS AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per MiRD II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

Where Global Research refers to "UBS Evidence Lab Inside" or has made use of data provided by UBS Evidence Lab you understand that UBS Evidence Lab is a separate department to Global Research and that UBS Evidence Lab does not provide research, investment recommendations or advice. UBS Evidence Lab may provide services to other internal and external clients.



Thank you for joining us today!

Upcoming webinars:



Anti-money laundering considerations for security and commodity derivatives



UK/EU - Rebuilding a relationship



NTFs: Key considerations for an emerging asset class



#